Dose related cardiomyopathy eppears to be unique to the anthracycline antibiotics (Unverferth et al., 1982) . Recent observations indicate that release of histamine and other vasoactive substances may be crucial in producing acute, subacute and chronic cardiotoxicity. In particular, adriamycin induces acute cardiovascular effects in dogs, that appear to be related to the release of histamine and catecholamines and to increased prostaglandin synthesis (Bristow et al., 1980) . There is evidence also that subacute cardiac damage in rabbits may be related to the release of vasoactive substances and pretreatment of animals with cromolyn produced significant protection against this type of cardiomyopathy (Bristow et al., 1983) . Chronic cardiac effects may also be related to histamine and catecholamine release, as, in rabbits, pretreatment with antihistamines and antiadrenergics prevents the majority of cardiac tissue damage (Bristow et al., 1981) . Adriamycin induces peritoneal mast cell degranulation when injected intraperitoneally in mice (Decorti et al., 1986a) ; in addition, this substance and other anthracyclines cause a significant and dose dependent histamine release from rat peritoneal cells in vitro in a non cytotoxic manner (Decorti et al., 1986b) .
The present study was undertaken with the aim of examining the effects of pretreatment with two substances able to interfere with histamine release, on the exocytotic response to adriamycin in vitro as well as on adriamycin-induced cardiomyopathy in vivo.
Materials and methods
In vitro studies Mixed peritoneal cells were obtained from 200-400 g male Sprague Dawley rats (Charles River, Italy) by lavage of the peritoneal cavities with saline solution at 37°C. The physiological solution had the following composition: 1.54 x 101 M NaCl, 2.7 x 10-3M KC1, 9 x 10-4 M CaCl2, 5.6 x O-3 M D-glucose, human serum albumin lgl-l and 10% by volume of a S6rensen buffer containing 3 x 10-2 M Na2HPO4 x7H2O and 3.5 x10-2 M NaH2PO 4xH2O. The pH of the solution was adjusted to 7.2.
The cells were sedimented by centrifugation at 200-250g for 10min, the supernatant fraction was removed and cells were resuspended in buffered medium at a concentration of 180,000-200,000 ml -1. A pooled suspension from more rats was employed for a day's experiment. The cell suspension contained -10% mast cells and was used without further purification because only the mast cells in such a suspension contain histamine (Lagunoff et al., 1983) .
In preliminary experiments adriamycin-induced histamine release was also tested on purified peritoneal mast cells.
Four Samples were incubated in quadruplicate for stated experimental times. Cells were separated from supernatants by centrifugation at -200g for 3min. The cell pellets were suspended in 400 dp saline solution and allowed to stand in a boiling water bath for 10min to release residual histamine; the supernatants of controls were processed similarly. All the samples were assayed for histamine by the fluorimetric method of Shore et al. (1959) , omitting the extraction step. The amount of histamine released was calculated as a percentage of the total histamine present in the control suspensions. All values were corrected for the spontaneous release (-5%) occurring in the absence of the inducers.
In vivo studies CD1 male mice (Charles River, Italy) of average wt 28-30 g, were used. Animals were divided into 9 groups of 20 animals each: group 1 received adriamycin alone 15mg kg-1 i.p.; group 2 received adriamycin as in group 1 plus theophylline 100 mg kg-1 i. 
Results
In vitro studies Figure 1 shows that adriamycin (100pgml-1) induces a significant histamine release from rat peritoneal mast cells. This concentration was used because it produced the most significant histamine release without disruption of cells. No difference in histamine release was observed when adriamycin was tested on purified mast cells (data not shown). Histamine release was significantly inhibited by various doses of theophylline and cromolyn ( Figure  1) , by high concentrations of n-acetylcysteine, but not of reduced glutathione. High concentrations of n-acetylcysteine were also efficacious in inhibiting histamine release induced by compound 48/80 (0.25 pg ml-1) (Figure 2 ).
In vivo studies Adriamycin, when administered i.p. in an acute (15 mg kg-1) or chronic (5 mg kg-1 week 1 x 3 weeks) regimen to CD1 mice, caused a severe drop in body wt and a high mortality rate. Pretreatment with theophylline and cromolyn prevented the decrease in body wt and significantly improved the survival time of the animals so treated (Figures 3  and 4) . The doses of the antagonists chosen were the highest ones devoid of toxicity.
The adriamycin-induced cardiac lesions observed in this study were similar to those previously described in other animal studies (Figures 5 and 6 ). These lesions were virtually absent in mice pretreated with theophylline or cromolyn (Figures 7  and 8) .
Discussion
The present study shows that substances able to inhibit adriamycin-induced histamine release from rat peritoneal mast cells in vitro, significantly ameliorate the survival time and the microscopic (Decorti et al., 1986a, b) . In studies performed by other authors (Riegel et al., 1982) , on the contrary, adriamycin did not produce significant histamine release on purified or unpurified rat mast cells in vitro, but caused a dose-related histamine release in vivo after i.p. injection. It should however be noted that in in vitro experiments performed in this paper, histamine was not directly measured, but the amount of serotonin released was calculated, assuming that the two substances behave identically.
Two substances known to inhibit 48/80-induced histamine release from rat peritoneal mast cells, theophylline (Loeffler et al., 1971 ) and disodium cromoglycate (Orr et al., 1971) have proved able to limit the release induced by adriamycin as well. These data together with the observations that theophylline and cromolyn are effective in ameliorating adriamycin-induced cardiotoxicity confirm the observations of other researchers (Bristow et al., 1980 (Bristow et al., , 1981 (Bristow et al., , 1983 ) indicating a major role for histamine in inducing adriamycin cardiotoxicity.
Among the various other pathogenetic hypotheses for adriamycin-induced cardiomyopathy, the generation of drug-induced reactive oxygen radicals in heart cells, leading to cardiac lipid membrane peroxidation, has been frequently advocated (Bachur et al., 1978; Myers et al., 1977) ; hence various agents acting' as free radical scavengers have been employed in the effort to prevent this side effect. N-acetylcysteine, in particular, significantly decreased lethality and ablated microscopic evidence of adriamycin cardiomyopathy in various experimental models (Doroshow et al., 1981; Kimball et al., 1979) . It is noteworthy that, in our in vitro system, N-acetyl- cysteine inhibited adriamycin as well as compound 48/80-induced histamine release, even if at very high doses. Among the several mechanisms initiating mast cell secretion and noncytotoxic release of histamine, are also oxidative metabolites like H202 (Ohmori et al., 1979) ; however we suggest that the mechanism of action of N-acetylcysteine is probably different from the free radical scavanging activity, as in our experimental system, it significantly limited also the release induced by compound 48/80. In addition, reduced glutathione, a free radical scavanger able to reduce the release of histamine induced by paracetamol (Brunelleschi et al., 1985) , was ineffective in limiting the mast cell secretion induced by adriamycin and compound 48/80. Our results indicating that substances able to inhibit histamine release in vitro can also prevent adriamycin cardiac toxicity in vivo, further support the hypothesis that histamine may play a role in the development of adriamycin cardiomyopathy. Hence the use of substances able to interfere with histamine release may provide a means to reduce the toxicity of this antineoplastic drug. This work was supported by grants from the 'Ministero della Pubblica Istruzione' and from C.N.R., Progetto Finalizzato 'Oncologia' contract n°84.00434.44.
